Aliases GABRA5
External IDs MGI: 95617 HomoloGene: 20219 GeneCards: GABRA5
Targeted by Drug
gaboxadol, isonipecotic acid, isoguvacine, muscimol, ZK93423, flumazenil, ZK93426, bretazenil, L-822179, methyl 6,7-dimethoxy-4-ethyl-β-carboline-3-carboxylate, ro-15-4513, RO4938581, L-838417, ocinaplon, alprazolam, flunitrazepam, triazolam, bicuculline, picrotoxin, CGS8216[1]
Species Human Mouse









RefSeq (mRNA)



RefSeq (protein)



Location (UCSC) Chr 15: 26.87 – 26.95 Mb Chr 7: 57.41 – 57.51 Mb
PubMed search [2] [3]
View/Edit HumanView/Edit Mouse

Gamma-aminobutyric acid (GABA) A receptor, alpha 5, also known as GABRA5, is a protein which in humans is encoded by the GABRA5 gene.[4][5]


GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABAA receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABAA receptor. At least 16 distinct subunits of GABAA receptors have been identified. Transcript variants utilizing three different alternative non-coding first exons have been described.[4]

Subunit selective ligands

Recent research has produced several ligands which are moderately selective for GABAA receptors containing the α5 subunit. These have proved to be useful in investigating some of the side effects of benzodiazepine and nonbenzodiazepine drugs, particularly the effects on learning and memory such as anterograde amnesia. Inverse agonists at this subunit have nootropic effects and may be useful for the treatment of cognitive disorders such as Alzheimer's disease.


Inverse agonists

See also


  1. "Drugs that physically interact with Gamma-aminobutyric acid receptor subunit alpha-5 view/edit references on wikidata".
  2. "Human PubMed Reference:".
  3. "Mouse PubMed Reference:".
  4. 1 2 "Entrez Gene: GABRA5 gamma-aminobutyric acid (GABA) A receptor, alpha 5".
  5. Wingrove P, Hadingham K, Wafford K, Kemp JA, Ragan CI, Whiting P (February 1992). "Cloning and expression of a cDNA encoding the human GABA-A receptor alpha 5 subunit". Biochem. Soc. Trans. 20 (1): 18S. PMID 1321750.
  6. McCabe, L. L.; McCabe, E. R. B. (2013). "Down syndrome and personalized medicine: Changing paradigms from genotype to phenotype to treatment". Congenital Anomalies. 53 (1): 1–2. doi:10.1111/cga.12000. PMID 23480351.
  7. Savić MM, Clayton T, Furtmüller R, et al. (2008). "PWZ-029, a compound with moderate inverse agonist functional selectivity at GABA(A) receptors containing alpha5 subunits, improves passive, but not active, avoidance learning in rats". Brain Res. 1208: 150–9. doi:10.1016/j.brainres.2008.02.020. PMC 2577822Freely accessible. PMID 18394590.
  8. van Niel MB, Wilson K, Adkins CH, et al. (2005). "A new pyridazine series of GABAA alpha5 ligands". J. Med. Chem. 48 (19): 6004–11. doi:10.1021/jm050249x. PMID 16162003.
  9. Ballard TM, Knoflach F, Prinssen E, et al. (2008). "RO4938581, a novel cognitive enhancer acting at GABA(A) alpha5 subunit-containing receptors". Psychopharmacology (Berl.). 202 (1–3): 207–23. doi:10.1007/s00213-008-1357-7. PMID 18936916.
  10. Chambers MS, Atack JR, Bromidge FA, et al. (2002). "6,7-Dihydro-2-benzothiophen-4(5H)-ones: a novel class of GABA-A alpha5 receptor inverse agonists". J. Med. Chem. 45 (6): 1176–9. doi:10.1021/jm010471b. PMID 11881985.
  11. Chambers MS, Atack JR, Broughton HB, et al. (2003). "Identification of a novel, selective GABA(A) alpha5 receptor inverse agonist which enhances cognition". J. Med. Chem. 46 (11): 2227–40. doi:10.1021/jm020582q. PMID 12747794.

Further reading

External links

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

This article is issued from Wikipedia - version of the 5/31/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.